Response to Hadinegoro et al.

Vaccine

Volumn 34, Issue 36, 2016, Pages 4275-

  Halstead, Scott B ^a   Russell, Philip K ^b  

^a Pediatric Dengue Vaccine Initiative   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NONSTRUCTURAL PROTEIN 1;

DENGUE; DENGUE VIRUS; DRUG SAFETY; HOSPITALIZATION; HUMAN; INFECTION RATE; LETTER; PRIORITY JOURNAL; VACCINATION; YELLOW FEVER;

EID: 84981311893     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.013     Document Type: Letter

References (3)

1. [1] Hadinegoro, S.R.S., Arredondo-García, J.L., Guy, B., Bouckenooghe, A., Noriega, F., Jackson, N., Answer to the review from Halstead and Russell “Protective and immunological behavior of chimeric yellow fever dengue vaccine”. Vaccine, 2016, 10.1016/j.vaccine.2016.06.015.
2. [2] Halstead, S.B., Russell, P.K., Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 34 (2016), 1643–1647, 10.1016/j.vaccine.2016.02.004.
3. [3] WHO. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. In: Department of Immunization VaB, editor. Geneva (Switzerland): World Health Organization; 2008. p. 441.